

ABSTRACT Barcode Nanotech March 2022

- **Investment Rational**

Barcode Nanotech is a therapeutic company developing lipid-based nanoparticle delivery vehicles for precise target-site activity and release. Using its proprietary screening tool, Barcode Nanotech is generating hundreds of new nanoparticles that can be applied to a broad range of diseases, including various cancers and genetic disorders, considered incurable to date.
- **Business Strategy**

Barcode Nanotech will generate revenue within the next 2 years through strategic collaborations with leading pharmaceutical companies in search for new delivery vehicles while internally developing novel therapeutic formulations. The company is already generating additional unique IP in this rapidly growing, drug-delivery field.
- **Core Technology**

The company develops proprietary, lipid-based nanoparticles that deliver RNA/DNA therapeutic sequences to target cells and organs. These nanoparticles protect the therapeutic agent until it safely reaches its target tissue.

Barcode is able to control the variables that affect nanoparticle performance, such as size, lipid composition, surface charge and ligand, to effectively deliver the specific therapeutic agent to its target.
- **Product Profile/Pipeline**

Barcode Nanotech holds unique IP for compositions of lipid-based nanoparticles with DNA based therapeutics for hard-to-treat cancers such as TNBC and ovarian cancers as well as delivery vehicles for RNA/DNA drugs in additional indications.
- **What's Next?**

The company is now finalizing a \$2M round to complete R&D and BD efforts which will drive co-development agreements with pharmaceutical companies and a \$10-15M round later this year.